Presidential Symposium II

LINK to Presidential Symposium II

LINK to STREAM (needs an ESMO registration)

LBA3_PR - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683

The abstract concludes: LungART is the first European randomized study evaluating modern PORT after complete resection, in pts selected predominantly with PET scan and having received (neo)adjuvant CT. 3-year DFS was higher than expected in both arms and PORT was associated with a non-statistically significant 15% increase in DFS among stage IIIAN2 pts.

Impact of COVID-19 on oncology professionals Watch now > (ecancer video)
Dr Susana Banerjee
The Royal Marsden NHS Foundation Trust, London, UK

Read also ESMO's Daily Reporter News: 

Planned Thoracic Radiotherapy Has No Role in the Management of Completely Resected pN2 NSCLC


LBA4 - IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)

The abstract concludes: In this primary endpoint analysis, ipat + abi as first-line treatment for mCRPC resulted in significantly improved rPFS and antitumor activity vs pbo + abi in pts with PTEN-loss mCRPC, but not in the ITT. The safety profile was in line with known and potential risks.


610O - Final overall survival (OS) analysis of PROfound: Olaparib vs physician’s choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

The abstract concludes: PROfound is the first phase 3 trial to show a PARP inhibitor benefit in alpha-controlled OS analyses. Despite extensive crossover from the control arm, olaparib conferred a statistically significant and clinically meaningful prolongation of OS vs sequential therapy with enzalutamide or abiraterone in men with mCRPC with progression on prior therapy and alterations in BRCA1, BRCA2 or ATM, with a 31% reduction in the risk for death.


Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

M. Hussain and Others

Read also ESMO's Daily Reporter News: 

PROfound: Overall Survival Data with Olaparib Herald Practice-changing Treatment of Metastatic Prostate Cancer


LBA5_PR - Abemaciclib in high risk early breast cancer

The abstract concludes: Abemaciclib when combined with ET is the first CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in IDFS in patients with HR+, HER2-, high risk EBC.

MonarchE: Abemaciclib plus endocrine therapy in high-risk early breast cancer  Watch now >  (ecancer video)
Prof Stephen Johnston
The Royal Marsden NHS Foundation Trust, London, UK